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Inhibition of matrix metalloproteinases prevents
peroxynitrite-induced contractile dysfunction in the
isolated cardiac myocyte
H Leo´n1, I Baczko´2, G Sawicki3, PE Light and R Schulz
Cardiovascular Research Group, University of Alberta, Edmonton, Alberta, Canada
Background and purpose: The potent oxidant peroxynitrite (ONOO) induces mechanical dysfunction in the intact heart in
part through activation of matrix metalloproteinase-2 (MMP-2). This effect may be independent of the proteolytic actions of
MMPs on extracellular matrix proteins. The purpose of this study was to examine the effects of ONOO on contractile function
at the level of the single cardiac myocyte and whether this includes the action of MMPs.
Experimental approach: Freshly isolated ventricular myocytes from adult rats were superfused with Krebs–Henseleit buffer at
21 1C and paced at 0.5 Hz. Contractility was measured using a video edge-detector. ONOO or decomposed ONOO (vehicle
control) were co-infused over 40 min to evaluate the contraction cease time (CCT). The effects of ONOO on intracellular
[Ca2þ ] were determined in myocytes loaded with calcium green-1 AM. MMP-2 activity was measured by gelatin zymography.
Key results: ONOO (30-600 mM) caused a concentration-dependent reduction in CCT. Myocytes subjected to 300 mM
ONOO had a shorter CCT than decomposed ONOO (14.9þ1.5 vs 32.2þ3.5 min, n¼7–8; Po0.05) and showed increased
MMP-2 activity. The MMP inhibitors doxycycline (100 mM) or PD 166793 (2 mM) reduced the decline in CCT induced by
300 mM ONOO. ONOO caused shorter calcium transient cease time and significant alterations in intracellular [Ca2þ ]
homoeostasis which were partially prevented by doxycycline.
Conclusions and implications: This is the first demonstration that inhibition of MMPs protects the cardiac myocyte from
ONOO-induced contractile failure via an action unrelated to proteolysis of extracellular matrix proteins.
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Introduction
The overproduction of reactive oxygen species including the
potent cellular oxidant peroxynitrite (ONOO) can outstrip
cellular antioxidant defences leading to oxidative stress
(Cai and Harrison, 2000; Ferdinandy and Schulz, 2003;
Ferdinandy, 2006; Pacher et al., 2007). This condition has
been implicated in the pathogenesis of many cardiovascular
diseases such as hypertension, atherosclerosis and the
complications resulting from diabetes and aging, and
heart-specific defects in myocarditis, heart failure (Ide
et al., 2000; Pacher et al., 2005) and ischaemia–reperfusion
injury (Wang and Zweier, 1996; Yasmin et al., 1997;
Crestanello et al., 1998).
Overproduction of reactive oxidant species can activate
matrix metalloproteinases (MMPs), enzymes best known
for their action in remodelling the extracellular matrix
(Rajagopalan et al., 1996; Okamoto et al., 2001; Siwik et al.,
2001). However, recent studies have unravelled new roles of
MMPs, particularly for matrix metalloproteinase-2 (MMP-2),
which is ubiquitous to most cell types including cardiac
myocytes (Coker et al., 2001; Wang et al., 2002b). These
include both physiological and pathological processes such
as platelet aggregation, inflammation and neurodegenerative
disease (Sawicki et al., 1997; McQuibban et al., 2000; Zhang
et al., 2003). In each of these conditions, the biological effect
of MMP-2, which is a rapid and early response of the cell to
enhanced oxidative stress, occurs by its proteolytic action on
novel substrates unrelated to extracellular matrix proteins
(Chow et al., 2007; Schulz, 2007). MMPs are implicated in
the pathogenesis of many cardiovascular diseases for their
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actions on both intracellular and extracellular targets in both
animal models and in human disease including myocardial
infarction (Rohde et al., 1999; Hayashidani et al., 2003;
Villarreal et al., 2003), heart failure (Rouet-Benzineb et al.,
1999; Spinale et al., 2000; Wilson et al., 2002), ischaemia–
reperfusion injury (Fujimura et al., 1999; Cheung et al., 2000;
Wang et al., 2002b; Schulze et al., 2003; Sawicki et al., 2005),
cytokine-induced cardiac dysfunction (Gao et al., 2003) and
sepsis (Yassen et al., 2001; Lalu et al., 2006). In addition,
cardiac preconditioning has shown to decrease the dele-
terious effects caused by MMP-2 in cardiac ischaemia–
reperfusion injury, an effect which is lost in hyperlipidemic
conditions (Lalu et al., 2002; Giricz et al., 2006).
ONOO is a potent oxidant that activates MMPs by
S-glutathiolation of a critical cysteine residue in their
propeptide domain resulting in a full-length active MMP
(Okamoto et al., 2001). We have previously shown that
infusion of ONOO into the isolated rat heart causes cardiac
contractile dysfunction through MMP-2, which is prevented
by MMP inhibition (Wang et al., 2002a). However, this
previous study did not directly address whether the detri-
mental effect of MMP-2 occurred via its proteolytic actions
on extracellular matrix proteins or on targets specifically
associated with the cardiac myocyte (Schulz, 2007).
In this regard, Ishida et al. (1996) showed that the direct
administration of ONOO to isolated neonatal cardiac
myocytes caused severe contractile dysfunction, evaluated
as the time taken for contractions to cease (contraction
cease time, CCT). However, whether MMPs are involved in
ONOO-induced contractile failure and alterations of
calcium handling in isolated adult cardiac myocytes is
unknown. Therefore, we hypothesized that ONOO pro-
duces contractile dysfunction through activation of MMPs
independent of their action on extracellular matrix proteins.
Methods
All the experiments were performed according to the
recommendations given by the Guide to the Care and Use of
Experimental Animals published by the Canadian Council on
Animal Care (revised 1993).
Isolation of cardiac myocytes
Calcium-tolerant ventricular myocytes were obtained by
enzymatic dissociation as described previously (Bouchard
et al., 1993; Light et al., 1998). Briefly, adult male Sprague–
Dawley rats (250–350 g) were anaesthetized with an injection
of sodium pentobarbital (60 mg kg1, i.p.). The hearts were
isolated and perfused through the aorta in a modified
Langendorff perfusion system at constant flow and at 37 1C
with oxygenated (95% O2: 5% CO2) Krebs–Henseleit solution
containing (in mM): NaCl (121), KCl (5), CH3COONa (1.7),
MgCl2 (0.1), Na2HPO4 (0.4), NaHCO3 (20.8), glucose (5.5),
taurine (1) and CaCl2 (1) for 5 min to clear any blood from
the coronary circulation. The solution was then switched to
a Ca2þ -free Krebs–Henseleit solution for 9 min. After this,
the solution was replaced for the first digestion process with
Krebs–Henseleit solution containing 40 mM Ca2þ and
13.3mg ml1 Streptomyces collagenase (Yalkut Pharmaceutical,
Tokyo, Japan) and 13.3 mg ml1 Streptomyces protease (Sigma,
Oakville, Ontario, Canada) for approximately 10 min. The
ventricles were then separated from the atria and great
vessels using scissors and chopped into small pieces. For the
second digestion process, the chopped tissue was placed into
a flask with Krebs–Henseleit solution containing 5.5 mM
HEPES, 3% BSA, 100 mM Ca2þ , and 83.3 mg ml1 collagenase
and 83.3 mg ml1 protease. The cells were further dissociated
by incubation at 37 1C under gentle agitation. A 2 ml aliquot
of cell suspension was removed after 10, 20, 30 and 40 min
incubation and centrifuged for 25 s at 2000 g. A volume of
2 ml of the second digestion buffer was replaced in the flask
each time after sampling. Each cell suspension was immedi-
ately centrifuged and the cells were resuspended in storage
buffer (Krebs–Henseleit solution containing 5.5 mM HEPES,
3% BSA and 100mM Ca2þ ). The aliquots were observed under
a light microscope for morphology and aliquots that showed
more than 70% rod-shaped cells (typically after 30 min
digestion) were used for experiments.
Synthesis of ONOO
Active and decomposed ONOO were synthesized, and the
concentration was verified on the same day of experiments
using ultraviolet spectroscopy as described previously
(Yasmin et al., 1997). Both active and decomposed ONOO
were diluted with 1 mM NaOH immediately prior to the
experiment to achieve the desired working concentration.
Measurement of myocyte contractility
To maintain a constant ONOO to myocyte ratio, approxi-
mately 5000 cardiac myocytes were placed into a perfusion
chamber in each experiment. Experiments were performed
at 21 1C to allow us to directly compare to the conditions
used by Ishida et al. (1996) and to facilitate the accurate
temporal measurement of cellular contracture. Freshly
isolated rat ventricular myocytes were continuously
superfused at 1 ml min1 with Krebs–Henseleit solution
containing 2 mM Ca2þ using an infusion pump (Cole-
Palmer, Barrington, IL, USA) and electrically paced at
0.5 Hz. Single myocyte contractility was measured using a
video edge-detector (Crescent Electronics, Salt Lake City, UT,
USA) and data were recorded using pClamp 8.0 software.
After 3 min, an infusion of either decomposed or authentic
ONOO was begun (using a microinfusion pump (Baxter,
Deerfield, IL, USA) linked via a side arm to the perfusion line
delivering Krebs–Henseleit solution), so that the final
concentrations of ONOO in the Krebs–Henseleit solution
reached either 30, 100 or 300 mM. The infusion was
continued for an experimental observation period of up to
a maximum of 40 min or until the time at which the cells
ceased to contract (CCT). A second series of cells were
perfused in an identical manner except that the MMP
inhibitors doxycycline (100 mM; Sigma) or PD 166793 (2 mM;
a kind gift from Pfizer, New York, NY, USA), dissolved in
Krebs–Henseleit solution, were used to superfuse the cells
after the 3 min baseline evaluation period. These MMPs
inhibitors at their respective concentrations were chosen
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based on previous data from isolated rat hearts subjected to
either ischaemia–reperfusion (Cheung et al., 2000; Wang
et al., 2002b; Schulze et al., 2003; Sawicki et al., 2005),
proinflammatory cytokines (Gao et al., 2003) or exogenous
ONOO (Wang et al., 2002a). Parallel experiments were
performed using their respective vehicles (water for doxy-
cycline and 0.05% dimethylsulphoxide v/v for PD 166793).
Although the previous studies (Cheung et al., 2000; Wang
et al., 2002b; Schulze et al., 2003; Sawicki et al., 2005)
indicated that doxycycline or PD 166793 does not have any
direct effect on myocardial contractile function in intact rat
hearts exposed to these drugs for up to 120 min, we also
evaluated whether these compounds could have any effect
on the contractile function of isolated cells. Infusion of the
inhibitors or their vehicles had no effect on contractile
function as observed over a 10 min period (data not shown).
Evaluation of MMP activity
The cell storage buffer was removed from an aliquot of freshly
isolated cardiac myocytes and replaced with Krebs–Henseleit
buffer containing 100mM Ca2þ (oxygenated with 95% O2: 5%
CO2) to reduce hypercontracture by three separate wash and
centrifugation steps (2000 g for 25 s). Cardiac myocytes
(B200 000 cells) in 3 ml buffer were then exposed to the bolus
addition of either 300mM ONOO or decomposed ONOO
followed by 5 min incubation at 21 1C. The addition of
ONOO or decomposed ONOO had no significant effect
on buffer pH. Cells were separated from the media by
centrifugation (2000 g for 40 s) and the latter was concen-
trated 20 times using Amicon Ultra-4 centricon tubes
(Millipore, Bedford, MA, USA). Cell homogenates were
prepared in 350ml of homogenization buffer containing
50 mM Tris-HCl (pH 7.4), 3.1 mM sucrose, 1 mM dithiothreitol
(Fisher Scientific, Ottawa, Ontario, Canada), 1:1000 protease
cocktail inhibitor (P-8340; Sigma) and 0.1% Triton X-100 and
homogenized on ice using a sonicator (Misonix, Farmingdale,
NY, USA, 310 s with 60 s between each cycle). Gelatin
zymography was performed as described by Cheung et al.
(2000). Samples from cell homogenates and media were
applied to 8% polyacrylamide gels co-polymerized with
2 mg ml1 gelatin. After electrophoresis, gels were rinsed three
times for 20 min each in 2.5% Triton X-100 to remove sodium
dodecyl sulphate. Then the gels were washed twice in
incubation buffer (50 mM Tris-HCl, 5 mM CaCl2, 150 mM NaCl
and 0.05% NaN3) for 20 min each at room temperature and
then incubated in a fresh aliquot of the same at 37 1C. The gels
were stained in 2% Coomassie Brilliant Blue G/25% methanol/
10% acetic acid for 2 h and then destained for 1 h in 2%
methanol/4% acetic acid. Gels were scanned using a GS-800-
calibrated densitometer (Bio-Rad, Mississauga, Ontario,
Canada) and band densities were measured using SigmaGel
software (Jandel, San Rafael, CA, USA).
Evaluation of intracellular [Ca2þ ]
Cardiac myocytes placed in storage buffer were loaded for
30 min at room temperature and then for 30 min at 37 1C
with the Ca2þ -sensitive fluorescent probe calcium green-1
AM (4mM, dissolved in a mixture of dimethyl sulphoxide and
pluronic acid, 1:1 v/v; Molecular Probes, Eugene, OR, USA).
After loading, cells were washed and centrifuged twice
(2000 g for 25 s) with storage buffer and placed on cover-
slips for observation at 200 with an inverted microscope
(CK40; Olympus, Center Valley, PA, USA) while being
superfused with the same Krebs–Henseleit buffer used for
contractility measurements, and paced at 0.5 Hz at 21 1C. An
infusion of either decomposed or 300 mM ONOO was started
after the baseline recording over a period of 20 min via a side
arm using a microinfusion pump. Some cardiac myocytes
were exposed to doxycycline (100 mM) dissolved in Krebs–
Henseleit buffer 5 min before starting the infusion of 300 mM
ONOO and maintained during the 20 min exposure period.
A Photon Technology International (Model 814; Lawrence-
ville, NJ, USA) photomultiplier detection system and
Clampex software (version 8.1) was used for data acquisition
and analysis. Calcium Green-1 AM was excited at 480 nm
and the emitted light intensity at 520 nm was digitized and
stored. The parameters evaluated were the percentage of
change in the calcium transient amplitude vs baseline, the
time to cease calcium transients and the time for maximal
increase in diastolic calcium.
Data analysis and statistical procedures
Data are expressed as means±s.e.mean. Student’s t-test
(unpaired) or one-way ANOVA followed by post hoc analysis
using Tukey’s multiple comparison test was used for
statistical analysis, as appropriate. Po0.05 was the criterion
for significance. The n refers to the number of individual
cardiac myocytes tested. In all experiments, cells were tested
from X4 separate isolations of myocytes.
Results
Concentration-dependent contractile dysfunction by ONOO
To directly evaluate the effects of ONOO on contractile
dysfunction in the isolated cardiac myocyte, we used the CCT
as a measure of severely impaired contractility. This measure
was previously used in neonatal cardiac myocytes exposed to
ONOO (Ishida et al., 1996), although the effects of ONOO
on adult rat ventricular myocytes have not been documented.
The administration of decomposed ONOO did not affect
the CCT, compared to control conditions (32.5±3.5 vs
35.1±3.0 min; P40.05, n¼8 and n¼9, respectively)
(Figure 1a). However, in the presence of ONOO, there was a
concentration-dependent decrease in CCT (Figure 1b). As pH is
a potential variable in these experiments due to the alkaline
ONOO buffer, we monitored the effects of up to 300mM
ONOO or its vehicle, decomposed ONOO, on superfusate
pH and observed no change in pH.
MMP inhibitors do not alter baseline contractile properties of
isolated cardiac myocytes
Cardiac myocytes were treated with two different MMP
inhibitors (doxycycline or PD 116793) as well as their
respective vehicle controls (water for doxycycline and
0.05% dimethylsulphoxide for PD 166793; n¼5 per group
from four independent isolations). During the 10-min
perfusion period with MMP inhibitors, the cells contracted
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regularly and none of them ceased to contract. Moreover,
there was no evidence of early depolarizations or after-
depolarizations, as shown by the lack of alterations of the
contractile waveform of the traces or absence of significant
differences in cell shortening or the time to 50% relaxation
(data not shown).
MMP inhibitors prevent contractile dysfunction caused by ONOO
Cardiac myocytes were exposed to a continuous infusion of
300 mM ONOO in the presence or absence of the MMP
inhibitors (doxycycline or PD 166793) or their respective
vehicles. Administration of 300 mM ONOO caused a rapid
onset in contractile dysfunction in myocytes, which was
revealed as irregular contractions with early afterdepolariza-
tions and hypercontracture as the infusion of ONOO
progressed (Figure 2a). Myocytes challenged with 300 mM
ONOO in the presence of doxycycline or PD 166793
exhibited a significantly delayed onset of contractile dys-
function in comparison to ONOO alone (Figures 2b and c).
These data are summarized in Figure 2d.
Impairment in Ca2þ homoeostasis caused by ONOO is
attenuated by MMPs inhibitors
Alteration in calcium homoeostasis is a common mechanism
for dysfunctional excitation coupling in cardiac myocytes.
Therefore, to evaluate whether the protective effect of MMP
inhibition was related to possible effects on Ca2þ homoeo-
stasis, we measured calcium transients in cardiac myocytes
subjected to 300 mM ONOO. The generation, amplitude and
shape of Ca2þ transients in cardiac myocytes exposed to
decomposed ONOO were unaltered over the duration of
the experimental protocol (Figure 3a). In contrast, 300 mM
ONOO caused a progressive increase in diastolic [Ca2þ ] as
well as a time-dependent reduced peak systolic transient
amplitude (Figure 3b). Doxycycline treatment delayed the
onset of changes in Ca2þ homoeostasis but did not prevent
their occurrence, as alterations of Ca2þ transient shape in
the form of premature Ca2þ release were observed during
the experiment (Figure 3c), although at a later time.
However, in the presence of doxycycline, the peak Ca2þ
transient amplitude was better maintained in comparison to
ONOO alone.
Cardiac myocytes exposed to 300mM ONOO displayed a
significant increase in Ca2þ transient amplitude at 5min in
comparison to decomposed ONOO. Doxycycline treatment
normalized this variable to values equal to those obtained with
exposure to decomposed ONOO (Figure 4a). These data are
consistent with early alteration in Ca2þ homoeostasis induced
by ONOO. Furthermore, cardiac myocytes challenged with
ONOO had a significant reduction in the time to cease
calcium transients that was attenuated by doxycycline treat-
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Figure 2 Effects of MMP inhibitors on contraction cease time (CCT)
during 300 mM ONOO exposure. (a–c) Representative traces of cell
shortening in cardiac myocytes subjected to ONOO alone (a) or
with 100 mM doxycycline (b) or 2mM PD 166793. (c) In each panel,
the expanded time scale of the cell-shortening traces are shown at (i)
baseline recording and (ii) 10 min after infusion of 300mM ONOO.
(d) Summary analysis in terms of the CCT. n¼5–6 cells per group
from a total of five independent preparations. *Po0.05 vs ONOO.
MMP, matrix metalloproteinase; ONOO, peroxynitrite.
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Figure 1 Concentration-dependent effect of a continuous infusion
of ONOO for 40 min on contraction cease time (CCT) in isolated
cardiac myocytes. There was no effect of infusions of decomposed
ONOO (dec. ONOO) on the CCT. *Po0.05 vs control, n¼4–9
cells from a total of 6 independent preparations. ONOO,
peroxynitrite.
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ment (Figure 4b). Represented in terms of the time to reach
maximum diastolic [Ca2þ ] during the experimental protocol,
cardiac myocytes challenged with 300mM ONOO showed a
reduced time to maximum increase in diastolic [Ca2þ ] level
compared with decomposed ONOO. Doxycycline, however,
did not alter this variable (Figure 4c). Furthermore, we
performed an analysis of the decay rates by fitting to a
monoexponential function and found no differences in the
values of half-life (data not shown).
ONOO activates myocyte MMP-2
To evaluate whether ONOO was able to activate MMPs
when given as a bolus to an aliquot of cardiac myocytes,
gelatin zymography was performed on the concentrated
incubation media from cardiac myocytes to examine
changes in MMP-2 or MMP-9 activities. After 5 min exposure
to 300mM ONOO, there was a significant increase in 62 kDa
MMP-2 activity in the media, compared with the effects of
exposure to decomposed ONOO and no evidence of 72 kDa
activity (Figure 5). We did not observe any evidence of
MMP-9 activity (data not shown).
Discussion and conclusions
This study is the first demonstration that inhibition of MMPs
reduces ONOO-induced contractile dysfunction in isolated
cardiac myocytes, independent of the canonical actions of
MMPs on extracellular matrix proteins. Previously, we had
demonstrated that MMP-2 is activated in isolated rat hearts
challenged with ONOO and that a MMP inhibitor pre-
vented this dysfunction (Wang et al., 2002a). However, this
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Figure 4 Quantitative analysis of the effects of ONOO and
doxycycline (doxy) on calcium homoeostasis. (a) Percent change
in calcium transient amplitude at 5 min ONOO infusion. (b) Time
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total of four independent preparations. ONOO, peroxynitrite.
Peroxynitrite, MMPs and cardiac myocyte function
H Leo´n et al680
British Journal of Pharmacology (2008) 153 676–683
study did not determine whether the effect of the activation
of MMP-2 was independent of proteolysis of extracellular
matrix proteins.
During myocardial ischaemia–reperfusion injury, ONOO
is rapidly generated during the first few minutes of reper-
fusion, which precedes the activation and release of MMP-2
from the heart (Yasmin et al., 1997; Cheung et al., 2000). In
the current study, we observed an increase in 62 kDa MMP-2
activity in the conditioned cell medium following exposure
to ONOO. The release of MMP-2 from heart muscle is
understood to be a consequence of its activation by oxidative
stress (Cheung et al., 2000; Wang et al., 2002a, b) and may be
a means for the cell to protect itself from further proteolytic
stress. MMP-2 activation as a result of ischaemia–reperfusion
injury in the intact heart results in the cleavage of troponin I
and myosin light chain 1 (Wang et al., 2002b; Sawicki et al.,
2005). Whether the same event occurs during ONOO
exposure to the isolated myocytes is unknown. Our data
suggest that the effect of ONOO was in part mediated by
increased MMP activity as the contractile dysfunction was
diminished by two structurally independent MMPs inhibi-
tors, doxycycline or PD 166793, and was independent of an
action of MMPs to cleave extracellular matrix proteins in the
isolated myocytes studied here. We found that 100 mM
doxycycline was superior to 3 mM PD 166793 in preventing
the contractile dysfunction caused by ONOO. This could
be, to some extent, due to proposed ROS scavenging
properties of some tetracyclines at high concentrations
(Whiteman and Halliwell, 1997), in comparison to the lower
concentration used here at which it has marked MMP
inhibitor activity in heart tissue (Cheung et al., 2000).
To the best of our knowledge, ROS scavenging properties
have not been reported for PD 166793.
We focused our study on the effects of ONOO and
activation of MMPs on the contractile function of isolated
cardiac myocytes to rule out effects of MMPs on extracellular
matrix proteins. Our experimental model and the functional
parameters measured have some resemblance to the situa-
tion in myocardial ischaemia–reperfusion injury, which is
characterized by an increased [Ca2þ ]i implicated in contrac-
tile dysfunction. As reported in this study, alterations in
calcium handling and contractile function were observed in
isolated cardiac myocytes. In addition, in isolated perfused
rat hearts subjected to ischaemia–reperfusion injury (endo-
genous increase of ONOO), we found enhanced MMP-2
activity and degradation of troponin I and myosin light
chain-1 (Yasmin et al., 1997; Cheung et al., 2000; Wang et al.,
2002b; Sawicki et al., 2005) as also observed in isolated
guinea pig hearts exposed to ONOO (Rork et al., 2006).
Therefore, our results from single cardiomyocytes suggest a
possible intracellular action of MMPs and provide a plausible
mechanism for the deleterious effects of ONOO-mediated
MMPs activation during ischaemia–reperfusion injury at the
whole heart level.
ONOO can activate MMPs by different mechanisms. One
of these is the S-glutathiolation of the propeptide domain
which has been observed for MMP-1, -8 and -9 (Okamoto
et al., 2001). Moreover, it was suggested that activation of
MMPs by ONOO could be mediated by nitration of tyrosine
residues in the hinge region and further unfolding of the
pro-MMP (Rajagopalan et al., 1996) or by S-nitrosylation of
the cysteine residue in the propeptide domain, as observed
with MMP-9 on its activation by either ischaemia–reperfu-
sion or following administration of nitric oxide donors
(Gu et al., 2002). The effect of ONOO on MMP activity is
biphasic as higher concentrations of ONOO have clearly
been shown to inactivate MMPs (Owens et al., 1997;
Okamoto et al., 2001). However, ONOO was shown to
inhibit tissue inhibitors of MMPs (TIMP-1 and TIMP-2),
which could increase net gelatinolytic activity in the cells
(Frears et al., 1996; Chakraborti et al., 2004). Owing to
technical limitations of the whole heart experiments, we
could not determine the intracellular compartment(s) in
which activation of MMPs occurred on exposure to ONOO.
However, ONOO may cause cellular injury through several
mechanisms including protein modifications and the in-
activation of proteins involved in Ca2þ handling, such as
the nitration and inactivation of sarcoplasmic reticulum
Ca2þ ATPase in porcine cardiac sarcoplasmic reticulum
microsomes, with either 0.3 mM or 1 mM ONOO (Lokuta
et al., 2005). Furthermore, ONOO inhibited the Naþ /Ca2þ
exchanger in microsomes prepared from bovine smooth
muscle cells, an event accompanied by the activation of
MMP-2 and inhibition of TIMP-2 (Chakraborti et al., 2004).
Moreover, reactive oxygen species have deleterious effects on
Ca2þ homoeostasis in cardiac myocytes through their action
on a number of proteins including phospholamban and
calcium channels (Guerra et al., 1996; Sulakhe et al., 1997;
Eigel et al., 2004; Sharikabad et al., 2004). In this regard, we
observed alterations in both diastolic and systolic calcium
homoeostasis in the presence of ONOO and this effect was
partially reversed by MMPs inhibitors. However, our study
cannot determine which structure(s) related to calcium
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Figure 5 Gelatin zymography of media from cardiac myocytes
exposed to either decomposed ONOO (dec. ONOO) or 300mM
ONOO. Upper panel shows a representative zymogram. Lower
panel shows summary data of the densitometric analysis of 62 kDa
MMP-2 activity. Note that the HT1080 cell supernatant used as a
control is human MMP-2 which consists of both 72 and 64 kDa
forms, the latter which is slightly higher in molecular weight than
the 62 kDa rat MMP-2. *Po0.05 vs dec. ONOO, n¼3 experiments.
ONOO, peroxynitrite.
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handling are susceptible to degradation by MMPs. Therefore,
these results are consistent with the notion that ONOO
alters intracellular calcium handling and contractility
through mechanisms that involve activation of MMPs.
In addition, ONOO is known to alter proteins involved
in cardiac contractility including myofibrillar, cytoskeletal
and mitochondrial respiratory chain enzymes. These
changes include post-translational modifications of several
amino acids, such as cysteine oxidation of creatine kinase,
tyrosine nitration of cytoskeletal a-actinin and desmin along
with modifications in cysteine and tyrosine residues and
Fe–S bridges of mitochondrial proteins (see for review Pacher
et al., 2007). These alterations are likely to contribute to
contractile dysfunction that cannot be prevented by MMPs
inhibition, as our study reports. Recently, we identified
a-actinin as a further target of MMP-2 degradation in isolated
hearts infused with ONOO (Sung et al., 2007) and it is
tempting to speculate that ONOO-induced post-transla-
tional modifications may enhance the targeting of suscep-
tible proteins to proteolysis by MMP-2.
Ishida et al. (1996) showed that infusion of 200 mM ONOO
caused contractile dysfunction in isolated neonatal cardiac
myocytes and this effect was accompanied by impaired Ca2þ
homoeostasis. In our model using freshly isolated adult
cardiac myocytes, we also observed abnormalities in Ca2þ
homoeostasis due to ONOO. The MMP inhibitor doxycy-
cline delayed the onset but did not prevent the impairment
in Ca2þ homoeostasis caused by ONOO. However, we
observed in our experiments that the time to cease calcium
transient was delayed by doxycycline treatment and also
that there was a significant increase in Ca2þ transient
amplitude at 5 min, suggesting that the contractile dysfunc-
tion observed in this model is related to systolic Ca2þ
abnormalities and also to a loss of sensitivity to Ca2þ in the
contractile machinery. The loss of sensitivity of the cardiac
myofibrils for Ca2þ upon ONOO challenge has been shown
in isolated perfused rat hearts (Brunner and Wolkart, 2003).
In conclusion, we have demonstrated that inhibition of
MMPs partially reduces contractile dysfunction in isolated
cardiac myocytes resulting from their direct exposure to
ONOO. The effect of MMP activation in these cells is
independent of a proteolytic action on extracellular matrix
proteins. This provides further insight into the pathological
mechanisms related to myocardial injury following oxida-
tive stress. Detoxifying ONOO or inhibiting the activation
of MMPs or their enzymatic activity may be an effective
therapeutic strategy to lessen the impact of oxidative stress
on cardiomyocyte function in pathological conditions such
as ischaemia–reperfusion injury.
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